Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
β-Glucosidase is an enzyme (EC 3.2.1.21) that hydrolyzes β-D-glucosidic bonds in a variety of glycosides, oligosaccharides, and notably cellulose, releasing glucose. It is composed of polypeptide chains with conserved catalytic domains featuring a (β/α)8-barrel fold and critical glutamate residues for nucleophilic and acid/base catalysis at the active site. In nature, these enzymes are crucial for the breakdown of plant biomass, immune defense, symbiosis, and metabolism. In medicine, acid-β-glucosidase (a lysosomal variant known as glucocerebrosidase) is replaced via enzyme therapy to treat Gaucher disease. Industry uses various β-glucosidases for biofuel production, food processing, and cellulose hydrolysis. Their function and specificity depend on their glycoside hydrolase family, substrate preference, and structure, with broad variation among species.
Substrate hydrolysis via a two-step retaining mechanism involving nucleophilic attack and acid/base catalysis by active site glutamate residues. Enzyme replacement drugs restore deficient enzyme activity in lysosomal storage disorders.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on β-Glucosidase (BGL).